Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Pharmaceuticals (Nasdaq: OLMA) has announced the granting of stock options to 5 new employees as part of their inducement awards. The options allow the purchase of 64,900 shares of common stock at an exercise price of $3.34 per share, matching the company's last reported sale price on April 1, 2025.
The stock options, approved by Olema's Compensation Committee under the 2022 Inducement Plan, feature a four-year vesting schedule: 25% vests on the first anniversary, followed by 36 monthly installments over three years, contingent on continuous employment. The options have a 10-year term and comply with Nasdaq Listing Rule 5635(c)(4).
Positive
- Company demonstrates ability to attract new talent with equity compensation
- Stock options align new employee interests with shareholder value
Negative
- Potential future dilution from 64,900 new shares
News Market Reaction 1 Alert
On the day this news was published, OLMA gained 0.60%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 5 new employees to purchase an aggregate of 64,900 shares of the Company's common stock, effective as of April 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What are the terms of OLMA's April 2025 employee stock options grant?
How many new employees received stock options from OLMA in April 2025?
What is the exercise price for OLMA's April 2025 inducement stock options?
What is the vesting schedule for OLMA's April 2025 inducement grants?
